Testing a new treatment for rheumatoid arthritis
Treatments studied
Part of Bones, joints & muscles, Immune system & allergy, Skin clinical trials.
This study tests whether a new investigational drug called Natrunix, when combined with your usual methotrexate, can improve symptoms of moderate to severe rheumatoid arthritis. The goal is to reduce joint pain and swelling and help you feel better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old and weigh more than 40 kg (about 88 lbs).
- You must have moderate to severe rheumatoid arthritis and be currently taking methotrexate (10-25 mg/week) for at least 12 weeks.
- You must have at least 6 swollen and 6 tender joints, and have been on a stable dose of methotrexate for at least 4 weeks.
- You must agree to keep taking the same dose of methotrexate throughout the study and also take folic acid (5 mg or more) weekly.
- You must not have taken any biologic medicines (like Humira, Enbrel, etc.) or JAK inhibitors for your RA in the past.
- You must not have active infections, uncontrolled heart disease, or significant lab abnormalities (like low blood counts or abnormal liver/kidney tests).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new medication (BMS-986454) for people with rheumatoid arthritis who haven't responded well enough to methotrexate. It aims to see if the drug is safe and how it works in the body.
This study tests whether increasing the dose of methotrexate or switching from pills to injections can better control rheumatoid arthritis symptoms. It aims to find the best way to use this common medication to reduce joint pain and swelling.
This trial tests a new experimental antibody called GNC-038 for people with moderate to severe rheumatoid arthritis (RA) that hasn't responded well enough to standard treatments. It aims to see if targeting specific immune cells can reduce inflammation and improve symptoms.
This study tests a new investigational drug called SR-878 for people with rheumatoid arthritis. It aims to see if the drug is safe and tolerable. You may join if you are between 18 and 60, have RA for at least 3 months, and take a stable dose of methotrexate.
This Phase 3 study compares two ways to treat active rheumatoid arthritis: a TNF-blocking biologic versus a targeted pill treatment. It may help people who are not doing well on (or cannot tolerate) certain biologic therapies to find a better, more practical option.
This study compares two combination treatments for rheumatoid arthritis in people whose current methotrexate or leflunomide isn’t working well enough. It aims to see whether adding a targeted therapy works better than the standard add-on of sulfasalazine plus hydroxychloroquine.
Hear when a new Rheumatoid arthritis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.